Evidence map›Paper›PMID 30444896›Full record

ArticlePloS one2018

Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression.

Falguni Das, Nandini Ghosh-Choudhury, Doug Yoon Lee, Yves Gorin, Balakuntalam S Kasinath, Goutam Ghosh Choudhury

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Falguni DasDepartment of Medicine, UT Health San Antonio, San Antonio, Texas, United States of America.
Nandini Ghosh-ChoudhuryDepartment of Pathology, UT Health San Antonio, San Antonio, Texas, United States of America.
Doug Yoon LeeDepartment of Medicine, UT Health San Antonio, San Antonio, Texas, United States of America.
Yves GorinDepartment of Medicine, UT Health San Antonio, San Antonio, Texas, United States of America.
Balakuntalam S KasinathDepartment of Medicine, UT Health San Antonio, San Antonio, Texas, United States of America.
Goutam Ghosh ChoudhuryDepartment of Medicine, UT Health San Antonio, San Antonio, Texas, United States of America.ORCID 0000-0003-0101-5821
The University of Texas Health Science Center at San Antonio · US

Funding

New Molecular and Cellular Mechanisms of GlaucomaI01BX000361 · VA · KANSAS CITY VA MEDICAL CENTER · PI SURGUCHOV, ANDREI · 2009 to 2013
–
Mechanisms of Renal Cell InjuryI01BX000926 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI GHOSH CHOUDHURY, GOUTAM, SHARMA, KUMAR · 2011 to 2024
–
New Insights in Mechanisms of Renal InjuryI01BX001340 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI Kumar Sharma · 2012 to 2026
–
BLRD VA I01 BX000361BLRD VA I01 BX000926BLRD VA I01 BX001340
6 · The paper itself

Abstract

TGFβ promotes podocyte hypertrophy and expression of matrix proteins in fibrotic kidney diseases such as diabetic nephropathy. Both mTORC1 and mTORC2 are hyperactive in response to TGFβ in various renal diseases. Deptor is a component of mTOR complexes and a constitutive inhibitor of their activities. We identified that deptor downregulation by TGFβ maintains hyperactive mTOR in podocytes. To unravel the mechanism, we found that TGFβ -initiated noncanonical signaling controls deptor inhibition. Pharmacological inhibitor of PI 3 kinase, Ly 294002 and pan Akt kinase inhibitor MK 2206 prevented the TGFβ induced downregulation of deptor, resulting in suppression of both mTORC1 and mTORC2 activities. However, specific isoform of Akt involved in this process is not known. We identified Akt2 as predominant isoform expressed in kidney cortex, glomeruli and podocytes. TGFβ time-dependently increased the activating phosphorylation of Akt2. Expression of dominant negative PI 3 kinase and its signaling inhibitor PTEN blocked Akt2 phosphorylation by TGFβ. Inhibition of Akt2 using a phospho-deficient mutant that inactivates its kinase activity, as well as siRNA against the kinase markedly diminished TGFβ -mediated deptor suppression, its association with mTOR and activation of mTORC1 and mTORC2. Importantly, inhibition of Akt2 blocked TGFβ -induced podocyte hypertrophy and expression of the matrix protein fibronectin. This inhibition was reversed by the downregulation of deptor. Interestingly, we detected increased phosphorylation of Akt2 concomitant with TGFβ expression in the kidneys of diabetic rats. Thus, our data identify previously unrecognized Akt2 kinase as a driver of TGFβ induced deptor downregulation and sustained mTORC1 and mTORC2 activation. Furthermore, we provide the first evidence that deptor downstream of Akt2 contributes to podocyte hypertrophy and matrix protein expression found in glomerulosclerosis in different renal diseases.

Indexed as

Down-RegulationGene Expression Regulation, EnzymologicAnimalsCell LineChromonesFibronectinsHypertrophyMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MorpholinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationPodocytesProto-Oncogene Proteins c-aktPTEN Phosphohydrolase2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAkt2 protein, ratChromonesFibronectinsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MorpholinesmTOR protein, ratPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, ratTOR Serine-Threonine KinasesTransforming Growth Factor beta

Identifiers

PMID30444896
PMCPMC6239304
OpenAlexW2901242485

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.